Changes in Overall Survival over Time for Patients with de novo Metastatic Breast Cancer
The purpose of this study was to determine the change in overall survival (OS) for patients with de novo metastatic breast cancer (dnMBC) over time. We conducted a retrospective cohort study with 1981 patients with dnMBC diagnosed between January 1995 and December 2017 at The University of Texas MD...
Main Authors: | , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2021-05-01
|
Series: | Cancers |
Subjects: | |
Online Access: | https://www.mdpi.com/2072-6694/13/11/2650 |
id |
doaj-2a829cba593a4ab8a242399a0a5e75de |
---|---|
record_format |
Article |
spelling |
doaj-2a829cba593a4ab8a242399a0a5e75de2021-06-01T01:25:55ZengMDPI AGCancers2072-66942021-05-01132650265010.3390/cancers13112650Changes in Overall Survival over Time for Patients with de novo Metastatic Breast CancerToshiaki Iwase0Tushaar Vishal Shrimanker1Ruben Rodriguez-Bautista2Onur Sahin3Anjali James4Jimin Wu5Yu Shen6Naoto T. Ueno7Section of Translational Breast Cancer Research, Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USASection of Translational Breast Cancer Research, Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USASection of Translational Breast Cancer Research, Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USASection of Translational Breast Cancer Research, Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USASection of Translational Breast Cancer Research, Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USADepartment of Biostatistics, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USADepartment of Biostatistics, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USASection of Translational Breast Cancer Research, Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USAThe purpose of this study was to determine the change in overall survival (OS) for patients with de novo metastatic breast cancer (dnMBC) over time. We conducted a retrospective cohort study with 1981 patients with dnMBC diagnosed between January 1995 and December 2017 at The University of Texas MD Anderson Cancer Center. OS was measured from the date of diagnosis of dnMBC. OS was compared between patients diagnosed during different time periods: 5-year periods and periods defined according to when key agents were approved for clinical use. The median OS was 3.4 years. The 5- and 10-year OS rates improved over time across both types of time periods. A subgroup analysis showed that OS improved significantly over time for the estrogen-receptor-positive/HER2-positive (ER+/HER2+) subtype and exhibited a tendency toward improvement over time for the ER-negative (ER−)/HER2+ subtype. In addition, median OS was significantly longer in patients with non-inflammatory breast cancer (<i>p</i> = 0.02) and patients with ER+ disease, progesterone-receptor-positive disease, HER2+ disease, lower nuclear grade, locoregional therapy, and metastasis to a single organ (all <i>p</i> < 0.0001). These findings showed that OS at 5 and 10 years after diagnosis in patients with dnMBC improved over time. The significant improvements in OS over time for the ER+/HER2+ subtype and the tendency toward improvement for the ER−/HER2+ subtype suggest the contribution of HER2-targeted therapy to survival.https://www.mdpi.com/2072-6694/13/11/2650breast neoplasmsneoplasm metastasisinflammatory breast neoplasmssurvival analysis |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Toshiaki Iwase Tushaar Vishal Shrimanker Ruben Rodriguez-Bautista Onur Sahin Anjali James Jimin Wu Yu Shen Naoto T. Ueno |
spellingShingle |
Toshiaki Iwase Tushaar Vishal Shrimanker Ruben Rodriguez-Bautista Onur Sahin Anjali James Jimin Wu Yu Shen Naoto T. Ueno Changes in Overall Survival over Time for Patients with de novo Metastatic Breast Cancer Cancers breast neoplasms neoplasm metastasis inflammatory breast neoplasms survival analysis |
author_facet |
Toshiaki Iwase Tushaar Vishal Shrimanker Ruben Rodriguez-Bautista Onur Sahin Anjali James Jimin Wu Yu Shen Naoto T. Ueno |
author_sort |
Toshiaki Iwase |
title |
Changes in Overall Survival over Time for Patients with de novo Metastatic Breast Cancer |
title_short |
Changes in Overall Survival over Time for Patients with de novo Metastatic Breast Cancer |
title_full |
Changes in Overall Survival over Time for Patients with de novo Metastatic Breast Cancer |
title_fullStr |
Changes in Overall Survival over Time for Patients with de novo Metastatic Breast Cancer |
title_full_unstemmed |
Changes in Overall Survival over Time for Patients with de novo Metastatic Breast Cancer |
title_sort |
changes in overall survival over time for patients with de novo metastatic breast cancer |
publisher |
MDPI AG |
series |
Cancers |
issn |
2072-6694 |
publishDate |
2021-05-01 |
description |
The purpose of this study was to determine the change in overall survival (OS) for patients with de novo metastatic breast cancer (dnMBC) over time. We conducted a retrospective cohort study with 1981 patients with dnMBC diagnosed between January 1995 and December 2017 at The University of Texas MD Anderson Cancer Center. OS was measured from the date of diagnosis of dnMBC. OS was compared between patients diagnosed during different time periods: 5-year periods and periods defined according to when key agents were approved for clinical use. The median OS was 3.4 years. The 5- and 10-year OS rates improved over time across both types of time periods. A subgroup analysis showed that OS improved significantly over time for the estrogen-receptor-positive/HER2-positive (ER+/HER2+) subtype and exhibited a tendency toward improvement over time for the ER-negative (ER−)/HER2+ subtype. In addition, median OS was significantly longer in patients with non-inflammatory breast cancer (<i>p</i> = 0.02) and patients with ER+ disease, progesterone-receptor-positive disease, HER2+ disease, lower nuclear grade, locoregional therapy, and metastasis to a single organ (all <i>p</i> < 0.0001). These findings showed that OS at 5 and 10 years after diagnosis in patients with dnMBC improved over time. The significant improvements in OS over time for the ER+/HER2+ subtype and the tendency toward improvement for the ER−/HER2+ subtype suggest the contribution of HER2-targeted therapy to survival. |
topic |
breast neoplasms neoplasm metastasis inflammatory breast neoplasms survival analysis |
url |
https://www.mdpi.com/2072-6694/13/11/2650 |
work_keys_str_mv |
AT toshiakiiwase changesinoverallsurvivalovertimeforpatientswithdenovometastaticbreastcancer AT tushaarvishalshrimanker changesinoverallsurvivalovertimeforpatientswithdenovometastaticbreastcancer AT rubenrodriguezbautista changesinoverallsurvivalovertimeforpatientswithdenovometastaticbreastcancer AT onursahin changesinoverallsurvivalovertimeforpatientswithdenovometastaticbreastcancer AT anjalijames changesinoverallsurvivalovertimeforpatientswithdenovometastaticbreastcancer AT jiminwu changesinoverallsurvivalovertimeforpatientswithdenovometastaticbreastcancer AT yushen changesinoverallsurvivalovertimeforpatientswithdenovometastaticbreastcancer AT naototueno changesinoverallsurvivalovertimeforpatientswithdenovometastaticbreastcancer |
_version_ |
1721412412171616256 |